MDWD

13.5900.37%
EK

Ety Klinger

Chief Medical Officer

Dr. Ety Klinger, Ph.D, MBA, has been Chief Medical Officer at MediWound Ltd. from January 2026 and served as its Chief Research and Development Officer since May 2014 until 2026. Prior to joining MediWound, Dr. Klinger served as Vice President of Research and Development at Proteologics Ltd since July 2011, where she was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd. Prior to this, Dr. Klinger served in numerous leadership positions at Teva's global innovative R&D division and served as Teva's Board representative at various biotechnology companies. Dr. Klinger was a key member of the Copaxone(R) development team. As a project leader she led the chemistry, manufacture and control, preclinical, clinical and post-marketing R&D activities of various innovative treatments for multiple sclerosis (MS), autoimmune and neurological diseases. From 2006 to 2011, as a Senior Director at Teva Innovative R&D, Dr. Klinger was a member of Teva's global innovative R&D management team. From 2006 to 2008, she served as the Head of MS and Autoimmune Diseases at Teva and led the Life Cycle Management (LCM) R&D activities of Copaxone(R) and the multi-disciplinary LCM teams of many other innovative products. From September 2008 to May 2011, Dr. Klinger was a member of the Board of Proteologics. Dr. Klinger holds a B.Sc in Biology from the Hebrew University in Jerusalem, a M.Sc. and a Ph.D. in Biochemistry from Tel-Aviv University and an MBA degree from Tel Aviv University and Northwestern University.

Positions